English 
Français Press Releases
2023
| Download | ||
|---|---|---|
| 2023/09/25 | ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses |  |
| 2023/09/18 | ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update | |
| 2023/08/31 | ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners | |
| 2023/07/25 | ADOCIA announces Q2 2023 financial results and a €10 million financing operation | |
| 2023/07/05 | ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing | |
| 2023/06/01 | Listing of ADOCIA shares suspended | |
| 2023/05/15 | ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer | |
| 2023/04/25 | ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities | |
| 2023/04/20 | ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris | |
| 2023/03/15 | ADOCIA announces its annual results for 2022 and provides corporate and financial update | |
| 2023/01/30 | Adocia publishes its Letter to Shareholders | |
2022
| Download | ||
|---|---|---|
| 2022/12/21 | ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 | |
| 2022/12/01 | Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products | |
| 2022/10/25 | ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates | |
| 2022/10/06 | ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis | |
| 2022/10/03 | ADOCIA: Upcoming investor meetings | |
| 2022/09/19 | ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update | |
| 2022/09/15 | ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th | |
| 2022/09/07 | ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes | |
| 2022/08/24 | ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update | |
| 2022/06/23 | Adocia publishes its Letter to Shareholders | |
| 2022/06/21 | ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes | |
| 2022/06/16 | ADOCIA confirms its eligibility for the PEA–PME | |
| 2022/05/20 | ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris | |
| 2022/05/18 | ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update | |
| 2022/05/18 | ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao | |
| 2022/05/09 | ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao | |
| 2022/04/19 | ADOCIA announces its annual results for 2021 and presents an update on activities | |
| 2022/04/11 | ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao | |
| 2022/03/28 | Adocia strengthens its cash position by 19 million euros following a real estate transaction | |
| 2022/02/23 | ADOCIA announces 2021 fourth quarter financial results | |
| 2022/01/13 | ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2022/01/11 | Number of shares and voting rights of ADOCIA as of December 31st, 2021 | |
| 2022/01/06 | ADOCIA announces its financial calendar for 2022 | |
2021
| Download | ||
|---|---|---|
| 2021/12/20 | ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 | |
| 2021/12/13 | Adocia Files Patent for Technology to Enable Oral Drug Delivery of Peptides | |
| 2021/10/26 | Adocia announces 2021 third quarter financial results and a financing of €7 million | |
| 2021/10/14 | ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China | |
| 2021/09/21 | ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD | |
| 2021/09/10 | Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference | |
| 2021/09/07 | ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities | |
| 2021/08/23 | Number of shares and voting rights of ADOCIA as of July 31st, 2021 | |
| 2021/07/29 | Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2021/07/22 | ADOCIA Announces Second Quarter 2021 Financial Results | |
| 2021/06/29 | ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes | |
| 2021/06/15 | ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions | |
| 2021/06/08 | ADOCIA confirms its eligibility for the PEA–PME | |
| 2021/06/02 | ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 | |
| 2021/06/01 | ADOCIA reinforces its board of directors with the appointment of three new independent members. | |
| 2021/05/26 | ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps | |
| 2021/05/11 | ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 | |
| 2021/04/21 | ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 | |
| 2021/04/21 | ADOCIA Announces First Quarter 2021 Financial Results | |
| 2021/03/18 | ADOCIA Announces Financial Results 2020 And Provides Corporate Update. | |
| 2021/03/10 | Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes | |
| 2021/01/25 | Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao | |
| 2021/01/11 | Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes | |
2020
| Download | ||
|---|---|---|
| 2020/12/21 | Adocia announces its financial calendar for 2021 | |
| 2020/10/20 | Adocia Announces Third Quarter 2020 Financial Results | |
| 2020/09/22 | Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 | |
| 2020/09/15 | Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. | |
| 2020/09/07 | September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) | |
| 2020/09/03 | September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD). | |
| 2020/08/18 | Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. | |
| 2020/07/30 | Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S | |
| 2020/07/20 | Adocia Announces First Half 2020 Financial Results | |
| 2020/06/08 | Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience | |
| 2020/04/23 | Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes | |
| 2020/04/23 | Adocia announces the release of its Universal Reference Document for the year 2019 | |
| 2020/04/20 | Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon | |
| 2020/04/14 | Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 | |
| 2020/03/12 | Adocia Announces Full Year 2019 Financial Results | |
2019
| Download | ||
|---|---|---|
| 2019/12/17 | Adocia announces its financial calendar for 2020 | |
| 2019/12/11 | Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners | |
| 2019/10/22 | Adocia Announces Third Quarter 2019 Financial Results | |
| 2019/10/14 | Adocia obtains additional financial resources to accelerate its growth | |
| 2019/09/30 | Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case | |
| 2019/09/10 | Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD | |
| 2019/08/23 | Adocia announces the decision of the American Arbitration Association Tribunal | |
| 2019/07/17 | Adocia Presents First Half 2019 Financial Results | |
| 2019/06/06 | Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes | |
| 2019/06/04 | Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions | |
| 2019/04/15 | Adocia announces the release of its Reference Document for the year 2018 | |
| 2019/04/15 | Adocia announces first quarter 2019 financial results: cash position and revenue | |
| 2019/04/10 | Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin | |
| 2019/04/10 | Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris | |
| 2019/03/13 | Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position | |
| 2019/02/12 | Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 | |
| 2019/01/16 | Adocia confirms its financial calendar for 2019 | |
| 2019/01/03 | PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas | |
2018
| Download | ||
|---|---|---|
| 2018/12/20 | Adocia announces its financial calendar for 2019 | |
| 2018/10/23 | Adocia Announces Third Quarter 2018 Financial Results | |
| 2018/10/11 | Adocia informs about a civil action filed by Eli Lilly | |
| 2018/10/05 | Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon | |
| 2018/09/26 | Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) | |
| 2018/09/05 | Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes | |
| 2018/08/30 | Adocia Announces Update to Second Arbitration Against Eli Lilly & Company | |
| 2018/08/21 | Number of shares and voting rights of ADOCIA as of July 31, 2018 | |
| 2018/08/08 | American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly | |
| 2018/07/25 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2018/07/18 | Adocia Presents First Half 2018 Financial Results | |
| 2018/06/14 | Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions | |
| 2018/06/05 | Adocia to Participate in the Jefferies 2018 Global Healthcare Conference | |
| 2018/06/01 | Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine | |
| 2018/05/02 | Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao | |
| 2018/04/26 | Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. | |
| 2018/04/19 | Adocia announces the release of its Reference Document for the year 2017 | |
| 2018/04/16 | Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes | |
| 2018/04/16 | Adocia announces first quarter 2018 financial results: Cash position and revenue | |
| 2018/04/09 | Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon | |
| 2018/03/19 | ADOCIA announced its financial results for 2017 and its perspectives for 2018 | |
| 2018/02/09 | Adocia to Present at the 2018 BIO CEO & Investor Conference in New York | |
| 2018/02/06 | Adocia Files Additional Arbitration Claims Against Eli Lilly & Company | |
| 2018/01/25 | Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes | |
| 2018/01/08 | Adocia announces its financial calendar for 2018 | |
| 2018/01/04 | Adocia announces expanded use of BioChaperone® beyond diabetes | |
2017
| Download | ||
|---|---|---|
| 2017/12/06 | Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes | |
| 2017/11/20 | Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study | |
| 2017/10/11 | Adocia announces financial results for the third quarter 2017 | |
| 2017/09/05 | Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes | |
| 2017/07/26 | Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer | |
| 2017/07/19 | Adocia presents first half 2017 financial results | |
| 2017/06/07 | Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes | |
| 2017/06/06 | Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes | |
| 2017/06/01 | Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump | |
| 2017/06/01 | Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon | |
| 2017/05/30 | Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions | |
| 2017/05/30 | Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York | |
| 2017/05/19 | Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris | |
| 2017/04/18 | Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 | |
| 2017/04/18 | Adocia announces first quarter 2017 financial results | |
| 2017/04/13 | Number of shares and voting rights of Adocia as of March 31, 2017 | |
| 2017/03/21 | ADOCIA confirms its eligibility for the PEA – PME | |
| 2017/03/13 | Number of shares and voting rights of ADOCIA as of February 28, 2017 | |
| 2017/03/07 | ADOCIA announced its financial results for 2016 and its perspectives for 2017 | |
| 2017/02/14 | Adocia announces its revenue and cash position for 2016 | |
| 2017/02/13 | Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference | |
| 2017/01/27 | Adocia to hold conference call on Monday January 30, 2017 | |
| 2017/01/27 | Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro | |
| 2017/01/25 | Adocia to hold conference call providing an update on its programs | |
| 2017/01/19 | Adocia announces the transformation of its business model to increase the value of its projects | |
| 2017/01/05 | Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes | |
| 2017/01/04 | Adocia announces its financial calendar for 2017 | |
2016
| Download | ||
|---|---|---|
| 2016/12/16 | Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro | |
| 2016/11/10 | Adocia to Participate in Upcoming Investor Conferences | |
| 2016/11/07 | Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes | |
| 2016/10/27 | Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 | |
| 2016/10/12 | Adocia announces third quarter 2016 financial results | |
| 2016/09/22 | Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region | |
| 2016/09/20 | Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes | |
| 2016/09/19 | Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) | |
| 2016/09/08 | Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting | |
| 2016/09/07 | Adocia announces new BioChaperone program combining a basal insulin and GLP-1s | |
| 2016/08/25 | Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer | |
| 2016/07/20 | Adocia presents first half 2016 financial results | |
| 2016/07/05 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2016/06/08 | Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon | |
| 2016/06/06 | Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions | |
| 2016/06/02 | Adocia to Present at the Jefferies 2016 Global Healthcare Conference | |
| 2016/05/31 | Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects | |
| 2016/05/13 | Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris | |
| 2016/05/03 | Adocia strengthens its BioChaperone Combo patent portfolio | |
| 2016/04/27 | Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes | |
| 2016/04/14 | Adocia announces first quarter 2016 results | |
| 2016/04/11 | Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 | |
| 2016/04/11 | Adocia announces the release of its Reference Document, for the year 2015 | |
| 2016/03/25 | ADOCIA confirms its eligibility for the PEA – PME | |
| 2016/03/21 | Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board | |
| 2016/03/16 | Annual Financial Results 2015 | |
| 2016/03/14 | Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes | |
| 2016/02/16 | ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 | |
| 2016/02/04 | Adocia to Present at the 2016 Leerink Global Healthcare Conference | |
| 2016/01/29 | Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects | |
| 2016/01/08 | Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets | |
2015
| Download | ||
|---|---|---|
| 2015/12/16 | Adocia announces its financial calendar for 2016 | |
| 2015/12/15 | Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 | |
| 2015/12/11 | Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 | |
| 2015/11/25 | Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes | |
| 2015/11/19 | Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region | |
| 2015/11/04 | Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes | |
| 2015/10/13 | ADOCIA Reports Third Quarter 2015 Financial Results | |
| 2015/10/06 | Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy | |
| 2015/09/30 | Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes | |
| 2015/08/27 | Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes | |
| 2015/07/21 | Adocia presents financial results for the first half of 2015 highlighting strong growth | |
| 2015/07/10 | Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo | |
| 2015/06/26 | Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes | |
| 2015/06/15 | Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices | |
| 2015/05/28 | Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 | |
| 2015/05/26 | Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) | |
| 2015/05/04 | Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 | |
| 2015/04/29 | Adocia is now integrated into the EnterNext Tech 40 Index | |
| 2015/04/20 | Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon | |
| 2015/04/14 | Adocia announces first quarter 2015 results | |
| 2015/03/16 | Adocia will present its 2014 annual results and its perspectives of growth during a conference call | |
| 2015/03/10 | Adocia reports a strengthened cash position and intensifies clinical development | |
| 2015/03/05 | Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly | |
| 2015/02/17 | ADOCIA: annual revenue and net cash position for 2014 | |
| 2015/02/10 | Adocia: modification of the means allocated to the liquidity agreement | |
| 2015/02/05 | Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet | |
| 2015/01/20 | Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation | |
| 2015/01/09 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
2014
| Download | ||
|---|---|---|
| 2014/12/29 | ADOCIA announces its financial calendar for 2015 | |
| 2014/12/22 | ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow | |
| 2014/12/19 | Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology | |
| 2014/10/16 | ADOCIA Announces Third-quarter Financial 2014 Results | |
| 2014/09/30 | ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry | |
| 2014/09/09 | Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes | |
| 2014/08/25 | Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer | |
| 2014/07/24 | Adocia Reports Operational and Financial Results for the First Half of 2014 | |
| 2014/07/09 | Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes | |
| 2014/06/24 | ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) | |
| 2014/06/16 | ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) | |
| 2014/06/10 | Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 | |
| 2014/06/04 | Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 | |
| 2014/05/27 | Adocia initiates ADR program in the United States | |
| 2014/05/20 | Adocia: PR BC Lispro Initiation of phase 2a | |
| 2014/05/19 | Adocia Press Release Liquidity Agreement with Kepler | |
| 2014/05/06 | Termination of Liquidity Agreement with DSF Markets | |
| 2014/04/10 | Adocia: Ultra Fast Lispro Clinical Results | |
| 2014/04/10 | Adocia: Revenue Q1 2014 | |
| 2014/03/26 | Gerard Soula Interview – La bourse et la vie (Transcript) | |
| 2014/03/20 | Adocia: Annual results 2013 | |
| 2014/03/17 | Adocia: confirmation of positive clinical results Combo | |
| 2014/02/26 | Positive Clinical Results for Combo | |
| 2014/02/10 | Adocia: Annual revenue of EUR 5.6 M in 2013 | |
| 2014/01/28 | Adocia strengthens its diabetic foot ulcer patent portfolio | |
| 2014/01/20 | Half year report on Adocia’s liquidity agreement at December 2013 | |
| 2014/01/06 | Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin | |
2013
| Download | ||
|---|---|---|
| 2013/12/09 | Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors | |
| 2013/11/13 | Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog | |
| 2013/10/24 | Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M | |
| 2013/10/19 | Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère | |
| 2013/09/05 | Activity and results for the first half of 2013 | |
| 2013/07/29 | Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration | |
| 2013/07/15 | Half Year report on Adocia’s Liquidity agreement with BIL Finance | |
| 2013/04/26 | Release of 2012 Reference Document (French only) | |
| 2013/04/24 | Q1 2013 revenues | |
| 2013/04/23 | Liquidity agreement | |
| 2013/04/23 | PR Suspension liquidity agreement | |
| 2013/03/18 | Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency | |
| 2013/02/13 | ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 | |
| 2013/01/07 | Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences | |
2012
| Download | ||
|---|---|---|
| 2012/10/30 | Adocia announces the strong growth of its turnover | |
| 2012/10/22 | Adocia is extending its intellectual property to new formulations of monoclonal antibodies | |
| 2012/10/01 | EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany | |
| 2012/09/12 | Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde | |
| 2012/09/07 | DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India | |
| 2012/09/03 | Financial results and business report for the first half of 2012 | |
| 2012/09/02 | WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon | |
| 2012/06/13 | Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment | |
| 2012/05/30 | Additional contribution to Liquidity Agreement with Dexia Securities France (French only) | |
| 2012/04/26 | ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 | |
| 2012/04/23 | ADOCIA reports positive phase II clinical results | |
| 2012/04/02 | Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA | |
| 2012/03/15 | Liquidity agreement with Dexia Securities France (French only) | |
| 2012/03/15 | ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… | |
2023
| Download | ||
|---|---|---|
| 2023/09/18 | ADOCIA Announces First Half 2023 Financial Results and Provides a Business Update | |
| 2023/09/14 | Number of shares and voting rights of ADOCIA as of August 31st, 2023 | |
| 2023/09/13 | ADOCIA Announces the Availability of a Prospectus for the Admission to Trading of Shares Issued or likely to be Issued to IPF Partners on Exercise of its Warrants | |
| 2023/08/31 | ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners | |
| 2023/08/30 | Number of shares and voting rights of ADOCIA as of July 31st, 2023 | |
| 2023/07/31 | ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2023/07/27 | ADOCIA Announces the Availability of a Prospectus for its Capital Increase and Convertible Bond Issue | |
| 2023/07/25 | ADOCIA announces Q2 2023 financial results and a €10 million financing operation | |
| 2023/07/18 | ADOCIA confirms its eligibility for the PEA–PME | |
| 2023/07/12 | Number of shares and voting rights of ADOCIA as of June 30th, 2023 | |
| 2023/07/05 | ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing | |
| 2023/06/16 | Number of shares and voting rights of ADOCIA as of May 31st, 2023 | |
| 2023/06/01 | Listing of ADOCIA shares suspended | |
| 2023/05/16 | Number of shares and voting rights of ADOCIA as of April 30th, 2023 | |
| 2023/05/15 | ADOCIA Announces the Appointment of Olivier Soula as Chief Executive Officer | |
| 2023/04/27 | ADOCIA Announces the Release of its Universal Registration Document for the Year 2022 | |
| 2023/04/25 | ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities | |
| 2023/04/20 | ADOCIA announces its annual Shareholders’ meeting to be held on May 11, 2023 in Paris | |
| 2023/04/13 | Number of shares and voting rights of ADOCIA as of March 31st, 2023 | |
| 2023/03/17 | Number of shares and voting rights of ADOCIA as of February 28th, 2023 | |
| 2023/03/15 | ADOCIA announces its annual results for 2022 and provides corporate and financial update | |
| 2023/02/15 | Number of shares and voting rights of ADOCIA as of January 31st, 2023 | |
| 2023/01/30 | Adocia publishes its Letter to Shareholders | |
| 2023/01/23 | ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2023/01/16 | Number of shares and voting rights of ADOCIA as of December 31st, 2022 | |
| 2023/01/12 | ADOCIA Announces its financial calendar for 2023 | |
2022
| Download | ||
|---|---|---|
| 2022/12/29 | ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao | |
| 2022/12/21 | ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023 | |
| 2022/12/15 | Number of shares and voting rights of ADOCIA as of November 30th, 2022 | |
| 2022/12/01 | Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products | |
| 2022/11/16 | Number of shares and voting rights of ADOCIA as of October 31st, 2022 | |
| 2022/10/25 | ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates | |
| 2022/10/13 | Number of shares and voting rights of ADOCIA as of September 30th, 2022 | |
| 2022/10/06 | ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis | |
| 2022/10/03 | ADOCIA: Upcoming investor meetings | |
| 2022/09/19 | ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update | |
| 2022/09/15 | ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th | |
| 2022/09/14 | Number of shares and voting rights of ADOCIA as of August 31st, 2022 | |
| 2022/09/07 | ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes | |
| 2022/08/25 | Number of shares and voting rights of ADOCIA as of July 31st, 2022 | |
| 2022/08/24 | ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update | |
| 2022/07/20 | Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2022/07/11 | Number of shares and voting rights of ADOCIA as of June 30th, 2022 | |
| 2022/06/23 | Adocia publishes its Letter to Shareholders | |
| 2022/06/21 | ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes | |
| 2022/06/16 | ADOCIA confirms its eligibility for the PEA–PME | |
| 2022/06/14 | Number of shares and voting rights of ADOCIA as of May 31st, 2022 | |
| 2022/05/20 | ADOCIA Announces its annual Shareholders’ meeting to be held on June 28, 2022 in Paris | |
| 2022/05/18 | ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update | |
| 2022/05/18 | ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao | |
| 2022/05/13 | Number of shares and voting rights of ADOCIA as of April 30th, 2022 | |
| 2022/05/09 | ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao | |
| 2022/04/25 | ADOCIA Announces the Release of its Universal Registration Document for the Year 2021 | |
| 2022/04/19 | ADOCIA announces its annual results for 2021 and presents an update on activities | |
| 2022/04/15 | Number of shares and voting rights of ADOCIA as of March 31st, 2022 | |
| 2022/03/28 | Adocia strengthens its cash position by 19 million euros following a real estate transaction | |
| 2022/03/16 | Number of shares and voting rights of ADOCIA as of February 28th, 2022 | |
| 2022/02/23 | ADOCIA announces 2021 fourth quarter financial results | |
| 2022/02/15 | Number of shares and voting rights of ADOCIA as of January 31st, 2021 | |
| 2022/01/13 | ADOCIA Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2022/01/11 | Number of shares and voting rights of ADOCIA as of December 31st, 2021 | |
| 2022/01/06 | ADOCIA announces its financial calendar for 2022 | |
2021
| Download | ||
|---|---|---|
| 2021/12/20 | ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2022 | |
| 2021/12/15 | Number of shares and voting rights of ADOCIA as of November 30th, 2021 | |
| 2021/11/19 | Number of shares and voting rights of ADOCIA as of October 31st, 2021 | |
| 2021/10/26 | Adocia announces 2021 third quarter financial results and a financing of €7 million | |
| 2021/10/14 | ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China | |
| 2021/10/12 | Number of shares and voting rights of ADOCIA as of September 30th, 2021 | |
| 2021/09/13 | Number of shares and voting rights of ADOCIA as of August 31st, 2021 | |
| 2021/09/10 | Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference | |
| 2021/09/07 | ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities | |
| 2021/08/23 | Number of shares and voting rights of ADOCIA as of July 31st, 2021 | |
| 2021/07/29 | Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2021/07/22 | ADOCIA Announces Second Quarter 2021 Financial Results | |
| 2021/07/15 | Number of shares and voting rights of ADOCIA as of June 30th, 2021 | |
| 2021/06/15 | ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions | |
| 2021/06/10 | Number of shares and voting rights of ADOCIA as of May 31st, 2021 | |
| 2021/06/08 | ADOCIA confirms its eligibility for the PEA–PME | |
| 2021/06/01 | ADOCIA reinforces its board of directors with the appointment of three new independent members. | |
| 2021/05/26 | ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps | |
| 2021/05/17 | Number of shares and voting rights of ADOCIA as of April 30, 2021 | |
| 2021/05/11 | ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 | |
| 2021/04/21 | ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 | |
| 2021/04/21 | ADOCIA Announces First Quarter 2021 Financial Results | |
| 2021/04/19 | ADOCIA: Number of shares and voting rights of ADOCIA as of March 31st, 2021 | |
| 2021/03/18 | ADOCIA Announces Financial Results 2020 And Provides Corporate Update. | |
| 2021/03/17 | Number of shares and voting rights of ADOCIA as of February 28th, 2021 | |
| 2021/02/16 | Number of shares and voting rights of ADOCIA as of January 31, 2021 | |
| 2021/01/25 | Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao | |
| 2021/01/20 | Number of shares and voting rights of ADOCIA as of December 31, 2020 | |
| 2021/01/18 | Adocia Announces half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
2020
| Download | ||
|---|---|---|
| 2020/12/21 | Adocia announces its financial calendar for 2021 | |
| 2020/12/07 | Number of shares and voting rights of ADOCIA as of November 30, 2020 | |
| 2020/11/06 | Number of shares and voting rights of ADOCIA as of October 31, 2020 | |
| 2020/10/20 | Adocia Announces Third Quarter 2020 Financial Results | |
| 2020/10/09 | Number of shares and voting rights of ADOCIA as of September 30, 2020 | |
| 2020/09/22 | Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 | |
| 2020/09/08 | Number of shares and voting rights of ADOCIA as of August 31, 2020 | |
| 2020/09/07 | September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) | |
| 2020/08/25 | Number of shares and voting rights of ADOCIA as of July 31, 2020 | |
| 2020/08/18 | Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. | |
| 2020/07/20 | Adocia Announces First Half 2020 Financial Results | |
| 2020/07/10 | ADOCIA confirms its eligibility for the PEA – PME | |
| 2020/07/06 | Number of shares and voting rights of ADOCIA as of June 30, 2020 | |
| 2020/07/03 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2020/06/05 | Number of shares and voting rights of ADOCIA as of May 31, 2020 | |
| 2020/05/11 | Number of shares and voting rights of ADOCIA as of April 30, 2020 | |
| 2020/04/23 | Adocia announces the release of its Universal Reference Document for the year 2019 | |
| 2020/04/20 | Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon | |
| 2020/04/14 | Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 | |
| 2020/04/09 | Number of shares and voting rights of ADOCIA as of March 31, 2020 | |
| 2020/03/12 | Adocia Announces Full Year 2019 Financial Results | |
| 2020/03/05 | Number of shares and voting rights of ADOCIA as of February 28, 2020 | |
| 2020/02/06 | Number of shares and voting rights of ADOCIA as of January 31, 2019 | |
| 2020/01/10 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2020/01/07 | Number of shares and voting rights of ADOCIA as of December 31, 2019 | |
2019
| Download | ||
|---|---|---|
| 2019/12/17 | Adocia announces its financial calendar for 2020 | |
| 2019/12/11 | Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners | |
| 2019/12/06 | Number of shares and voting rights of ADOCIA as of November 30, 2019 | |
| 2019/11/07 | Number of shares and voting rights of ADOCIA as of October 31st, 2019 | |
| 2019/10/22 | Adocia Announces Third Quarter 2019 Financial Results | |
| 2019/10/14 | Adocia obtains additional financial resources to accelerate its growth | |
| 2019/10/04 | Number of shares and voting rights of ADOCIA as of September 30, 2019 | |
| 2019/09/30 | Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case | |
| 2019/09/09 | Number of shares and voting rights of ADOCIA as of August 31, 2019 | |
| 2019/08/06 | Number of shares and voting rights of ADOCIA as of July 31st 2019 | |
| 2019/07/17 | Adocia Presents First Half 2019 Financial Results | |
| 2019/07/11 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2019/07/05 | Number of shares and voting rights of ADOCIA as of June 30, 2019 | |
| 2019/06/11 | Number of shares and voting rights of ADOCIA as of May 31, 2019 | |
| 2019/05/07 | Number of shares and voting rights of ADOCIA as of April 30, 2019 | |
| 2019/04/15 | Adocia announces the release of its Reference Document for the year 2018 | |
| 2019/04/15 | Adocia announces first quarter 2019 financial results: cash position and revenue | |
| 2019/04/10 | Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris | |
| 2019/04/04 | Number of shares and voting rights of ADOCIA as of March 31, 2019 | |
| 2019/03/13 | Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position | |
| 2019/03/08 | Number of shares and voting rights of ADOCIA as of February 28, 2019 | |
| 2019/02/12 | Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 | |
| 2019/02/08 | Number of shares and voting rights of ADOCIA as of January 31, 2019 | |
| 2019/01/16 | Adocia confirms its financial calendar for 2019 | |
| 2019/01/10 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2019/01/10 | Number of shares and voting rights of ADOCIA as of December 31, 2018 | |
2018
| Download | ||
|---|---|---|
| 2018/12/20 | Adocia announces its financial calendar for 2019 | |
| 2018/12/06 | Number of shares and voting rights of ADOCIA as of November 30, 2018 | |
| 2018/11/07 | Number of shares and voting rights of ADOCIA as of October 31, 2018 | |
| 2018/10/23 | Adocia Announces Third Quarter 2018 Financial Results | |
| 2018/10/05 | Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon | |
| 2018/10/04 | Number of shares and voting rights of ADOCIA as of September 30, 2018 | |
| 2018/09/06 | Number of shares and voting rights of ADOCIA as of August 31, 2018 | |
| 2018/08/21 | Number of shares and voting rights of ADOCIA as of July 31, 2018 | |
| 2018/07/25 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2018/07/18 | Adocia Presents First Half 2018 Financial Results | |
| 2018/07/04 | Number of shares and voting rights of ADOCIA as of June 30, 2018 | |
| 2018/06/08 | Number of shares and voting rights of ADOCIA as of May, 31 2018 | |
| 2018/05/07 | Number of shares and voting rights of ADOCIA as of April, 30 2018 | |
| 2018/04/19 | Adocia announces the release of its Reference Document for the year 2017 | |
| 2018/04/16 | Number of shares and voting rights of ADOCIA as of March, 31 2018 | |
| 2018/04/16 | Adocia announces first quarter 2018 financial results: Cash position and revenue | |
| 2018/04/09 | Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon | |
| 2018/03/19 | ADOCIA announced its financial results for 2017 and its perspectives for 2018 | |
| 2018/03/16 | ADOCIA confirms its eligibility for the PEA – PME | |
| 2018/03/06 | Number of shares and voting rights of ADOCIA as of February 28, 2018 | |
| 2018/02/12 | Number of shares and voting rights of ADOCIA as of January 31, 2018 | |
| 2018/02/12 | Adocia: additional resources allocated to the liquidity agreement | |
| 2018/01/10 | Number of shares and voting rights of ADOCIA as of December 31, 2017 | |
| 2018/01/09 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2018/01/08 | Adocia announces its financial calendar for 2018 | |
2017
| Download | ||
|---|---|---|
| 2017/12/07 | Number of shares and voting rights of ADOCIA as of November 30, 2017 | |
| 2017/11/08 | Number of shares and voting rights of ADOCIA as of October 31, 2017 | |
| 2017/10/12 | Number of shares and voting rights of ADOCIA as of September 30, 2017 | |
| 2017/10/11 | Adocia announces financial results for the third quarter 2017 | |
| 2017/09/18 | Number of shares and voting rights of ADOCIA as of August 31, 2017 | |
| 2017/07/19 | Adocia presents first half 2017 financial results | |
| 2017/07/11 | Number of shares and voting rights of ADOCIA as of June 30, 2017 | |
| 2017/07/10 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2017/06/09 | Number of shares and voting rights of ADOCIA as of May 31, 2017 | |
| 2017/05/19 | Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris | |
| 2017/04/18 | Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 | |
| 2017/04/18 | Adocia announces first quarter 2017 financial results | |
| 2017/04/13 | Number of shares and voting rights of Adocia as of March 31, 2017 | |
| 2017/03/21 | ADOCIA confirms its eligibility for the PEA – PME | |
| 2017/03/13 | Number of shares and voting rights of ADOCIA as of February 28, 2017 | |
| 2017/03/07 | ADOCIA announced its financial results for 2016 and its perspectives for 2017 | |
| 2017/02/14 | Adocia announces its revenue and cash position for 2016 | |
| 2017/01/19 | Adocia announces the transformation of its business model to increase the value of its projects | |
| 2017/01/06 | Half year report on Adocia’s liquidity agreement with Kepler Chevreux | |
| 2017/01/04 | Adocia announces its financial calendar for 2017 | |
2016
| Download | ||
|---|---|---|
| 2016/10/12 | Adocia announces third quarter 2016 financial results | |
| 2016/07/20 | Adocia presents first half 2016 financial results | |
| 2016/05/13 | Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris | |
| 2016/05/03 | Adocia strengthens its BioChaperone Combo patent portfolio | |
| 2016/04/27 | Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes | |
| 2016/04/14 | Adocia announces first quarter 2016 results | |
| 2016/04/11 | Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 | |
| 2016/04/11 | Adocia announces the release of its Reference Document, for the year 2015 | |
| 2016/03/21 | Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board | |
| 2016/03/16 | Annual Financial Results 2015 | |
| 2016/02/16 | ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 | |
| 2016/01/08 | Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets | |
2015
| Download | ||
|---|---|---|
| 2015/12/16 | Adocia announces its financial calendar for 2016 | |
| 2015/12/15 | Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 | |
| 2015/10/13 | ADOCIA Reports Third Quarter 2015 Financial Results | |
| 2015/10/06 | Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy | |
| 2015/10/05 | Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon | |
| 2015/09/17 | ADOCIA: additional contribution to the liquidity agreement | |
| 2015/07/21 | Adocia presents financial results for the first half of 2015 highlighting strong growth | |
| 2015/07/07 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2015/06/15 | Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices | |
| 2015/05/04 | Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 | |
| 2015/04/20 | Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon | |
| 2015/04/14 | Adocia announces first quarter 2015 results | |
| 2015/03/16 | Adocia will present its 2014 annual results and its perspectives of growth during a conference call | |
| 2015/03/10 | Adocia reports a strengthened cash position and intensifies clinical development | |
| 2015/02/17 | ADOCIA: annual revenue and net cash position for 2014 | |
| 2015/02/10 | Adocia: modification of the means allocated to the liquidity agreement | |
| 2015/01/09 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
2014
| Download | ||
|---|---|---|
| 2014/12/29 | ADOCIA announces its financial calendar for 2015 | |
| 2014/10/16 | ADOCIA Announces Third-quarter Financial 2014 Results | |
| 2014/07/24 | Adocia Reports Operational and Financial Results for the First Half of 2014 | |
| 2014/07/10 | Half year report on Adocia’s liquidity agreement with Kepler Capital Markets | |
| 2014/06/24 | ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) | |
| 2014/06/16 | ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) | |
| 2014/06/10 | Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 | |
| 2014/05/27 | Adocia initiates ADR program in the United States | |
| 2014/05/20 | Adocia: PR BC Lispro Initiation of phase 2a | |
| 2014/05/19 | Adocia Press Release Liquidity Agreement with Kepler | |
| 2014/05/06 | Termination of Liquidity Agreement with DSF Markets | |
| 2014/04/10 | Adocia: Revenue Q1 2014 | |
| 2014/03/20 | Adocia: Annual results 2013 | |
| 2014/02/10 | Adocia: Annual revenue of EUR 5.6 M in 2013 | |
| 2014/01/29 | 2014 Financial Calendar | |
| 2014/01/20 | Half year report on Adocia’s liquidity agreement at December 2013 | |
2013
| Download | ||
|---|---|---|
| 2013/10/24 | Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M | |
| 2013/09/05 | Activity and results for the first half of 2013 | |
| 2013/07/15 | Half Year report on Adocia’s Liquidity agreement with BIL Finance | |
| 2013/04/26 | Release of 2012 Reference Document (French only) | |
| 2013/04/24 | Q1 2013 revenues | |
| 2013/04/23 | Liquidity agreement | |
| 2013/04/23 | PR Suspension liquidity agreement | |
| 2013/03/20 | 2012 Annual Results | |
| 2013/02/13 | ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 | |
| 2013/01/07 | Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences | |
2012
| Download | ||
|---|---|---|
| 2012/10/30 | Adocia announces the strong growth of its turnover | |
| 2012/09/24 | Large & Midcap Event – 24-25 September 2012, Paris | |
| 2012/09/04 | SFAF meeting – Half year 2012 results. At 14:30, NYSE EURONEXT, room Auditorium – 3 rue Cambon – 75001 Paris | |
| 2012/09/03 | Financial results and business report for the first half of 2012 | |
| 2012/05/30 | Additional contribution to Liquidity Agreement with Dexia Securities France (French only) | |
| 2012/04/26 | ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 | |
| 2012/04/02 | Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA | |
| 2012/03/15 | Liquidity agreement with Dexia Securities France (French only) | |
| 2012/03/15 | ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… | |